Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation

Cell Cycle

Volumn 10, Issue 5, 2011, Pages 794-804

  Raven, Jennifer F ^a,e   Williams, Virginie ^a   Wang, Shuo ^a   Tremblay, Michel L ^b   Muller, William J ^b   Durbin, Joan E ^d   Koromilas, Antonis E ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

Chemotherapeutic drugs; ErbB2 Neu oncoprotein; Malignant transformation; Mammary gland tumorigenesis; Protein phosphorylation; Transcription factor stat1; Transgenic mouse; Xenograft and tumor transplantation assays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; LAPATINIB; STAT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 79952344515     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.5.14956     Document Type: Article

References (56)

1. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-62. (Pubitemid 34987786)
2. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282:20059-63. (Pubitemid 47099977)
3. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008; 18:443-51. (Pubitemid 351498851)
4. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2:315-24. (Pubitemid 40903176)
5. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-48. (Pubitemid 44631652)
6. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61. (Pubitemid 28293291)
7. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165:3571-7. (Pubitemid 32057258)
8. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10:77-87.
9. Yu H, Jove R. The stats of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105. (Pubitemid 38198738)
10. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109:1139-42. (Pubitemid 34496590)
11. kip1. PLoS ONE 2008; 3:3476.
12. Wang S, Koromilas AE. Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells. Cell Cycle 2009; 8:2070-9.
13. Kip1 stabilization in Ras-transformed cells. Mol Cancer Res 2010; 8:798-805.
14. Yoshimura A. Stat1 phosphorylation is a molecular switch of Ras signaling and oncogenesis. Cell Cycle 2009; 8:1981-2.
15. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-16. (Pubitemid 44036456)
16. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358:1160-74.
17. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75.
18. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007; 43:481-9. (Pubitemid 46178540)
19. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001; 7:1497-504. (Pubitemid 32708611)
20. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-6.
21. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103-11. (Pubitemid 43736610)
22. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008; 15:367-90. (Pubitemid 351880829)
23. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165:1449-60. (Pubitemid 39435145)
24. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res 2009; 69:6823-30.
25. Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA 2006; 103:9773-8. (Pubitemid 43993573)
26. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999; 274:17209-18.
27. Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE Jr. Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ 1998; 9:505-12. (Pubitemid 28345907)
28. Nyati MK, Morgan MA, Feng FY, Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6:876-85. (Pubitemid 44629899)
29. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-9. (Pubitemid 43259947)
30. Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997; 17:5410-25. (Pubitemid 27357639)
31. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 2000; 275:24935-44. (Pubitemid 30626601)
32. Leaman DW, Pisharody S, Flickinger TW, Commane MA, Schlessinger J, Kerr IM, et al. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol Cell Biol 1996; 16:369-75. (Pubitemid 126506983)
33. Soond SM, Townsend PA, Barry SP, Knight RA, Latchman DS, Stephanou A. ERK and the F-box protein betaTRCP target STAT1 for degradation. J Biol Chem 2008; 283:16077-83.
34. Varinou L, Ramsauer K, Karaghiosoff M, Kolbe T, Pfeffer K, Muller M, et al. Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity 2003; 19:793-802. (Pubitemid 37542300)
35. Kim JB, Stein R, O'Hare MJ. Three-dimensional in vitro tissue culture models of breast cancer - a review. Breast Cancer Res Treat 2004; 85:281-91. (Pubitemid 38987263)
36. Lee MY, Joung YH, Lim EJ, Park JH, Ye SK, Park T, et al. Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells. Breast 2006; 15:187-95.
37. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 1999; 18:2149-64. (Pubitemid 29179172)
38. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 1996; 84:443-50. (Pubitemid 26058569)
39. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007; 7:389-97. (Pubitemid 46652484)
40. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11. (Pubitemid 32391043)
41. Cardiff RD, Munn RJ, Galvez JJ. The Tumor Pathology of Genetically Engineered Mice: A New Approach to Molecular Pathology. In: In: Fox JG, Davisson MT, Quimby FW, Barthold SW, Newcomer CE, Smith AL, Editors. The Mouse in Biomedical Research: Experimental Biology and Oncology Second ed. New York: Elsevier 2006; 581-622.
42. Cardiff RD, Sinn E, Muller W, Leder P. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am J Pathol 1999; 139:495-501.
43. Radaelli E, Damonte P, Cardiff RD. Epithelial-mesenchymal transition in mouse mammary tumorigenesis. Future Oncol 2009; 5:1113-27.
44. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, et al. Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol 2009; 46:736-45.
45. Wong LL, Chang CF, Koay ES, Zhang D. Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression. Int J Oncol 2009; 34:1291-301.
46. Watson CJ. Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2001; 6:115-27. (Pubitemid 33640650)
47. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002; 8:3065-74. (Pubitemid 35155015)
48. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010; 29:920-9.
49. Ilkovitch D, Handel-Fernandez ME, Herbert LM, Lopez DM. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res 2008; 68:2427-35. (Pubitemid 351521818)
50. Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res 2007; 67:9214-20. (Pubitemid 47535908)
51. Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE 2009; 4:5821.
52. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA 2008; 105:18490-5.
53. Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG, et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res 2004; 64:8357-64. (Pubitemid 39491775)
54. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14:2015-27. (Pubitemid 30637352)
55. Wong AH, Durbin JE, Li S, Dever TE, Decker T, Koromilas AE. Enhanced antiviral and antiproliferative properties of a STAT1 mutant unable to interact with the protein kinase PKR. J Biol Chem 2001; 276:13727-37.
56. Jessen KA, Liu SY, Tepper CG, Karrim J, McGoldrick ET, Rosner A, et al. Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 2004; 6:157-69.